AI assistant
Biocon Ltd. — Capital/Financing Update 2025
Dec 23, 2025
61176_rns_2025-12-23_0b898d26-f605-41f3-bac5-47d35425a966.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [132 x 53] intentionally omitted <==
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com
BIO/SECL/TG/2025-26/144
December 23, 2025
| ToThe Manager,BSE LimitedDepartment of Corporate ServicesPhiroze Jeejeebhoy Towers,Dalal Street,Mumbai – 400 001 | ToThe Manager,National Stock Exchange of India LimitedCorporate Communication DepartmentExchange Plaza, Bandra Kurla ComplexMumbai – 400 050 |
|---|---|
| Scrip Code - 532523 | Scrip Symbol - BIOCON |
Dear Sir/ Madam,
Subject: Press Release
Please find enclosed the press release titled “ Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement”.
The above information will also be available on the website of the Company at www.biocon.com.
Kindly take the same on record and acknowledge.
Thanking You,
Yours faithfully,
For Biocon Limited
RAJESH Digitally signed by RAJESH UMAKANT UMAKANT SHANOY SHANOY Date: 2025.12.23 09:03:09 +05'30'
Rajesh U. Shanoy Company Secretary and Compliance Officer M. No.: ACS 16328
Encl: Press Release
PRESS RELEASE
==> picture [80 x 30] intentionally omitted <==
==> picture [132 x 30] intentionally omitted <==
Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
Bengaluru, Karnataka, India: December 23, 2025:
Biocon Biologics Limited , a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), today announced that it has secured full and exclusive global rights for Hulio® (biosimilar Adalimumab) from Fujifilm Kyowa Kirin Biologics Co., Ltd. (FKB). Under this new agreement, Biocon Biologics will assume end-to-end responsibility for manufacturing and commercialization along with rights for any additional development activities.
The new agreement supersedes the existing collaboration agreement between Biocon Biologics and FKB for biosimilar Adalimumab, under which Biocon Biologics only had commercialization rights.
Under the terms of this agreement, FKB will participate in the development of the product and will offset certain development costs incurred by Biocon Biologics. In turn, Biocon Biologics will pay a technology license fee and royalties on sales to FKB for a specified tenure.
Commercial production of biosimilar Adalimumab at Biocon Biologics’ facilities will commence following successful technology transfer and regulatory approvals.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited, said: “This agreement with FKB provides Biocon Biologics the manufacturing rights to biosimilar Adalimumab, granting us end-to-end control over the product. This strategic move enhances flexibility and cost efficiency, reinforcing our commitment to expanding affordable access to high-quality biologics for patients with inflammatory diseases globally.”
Biocon Biologics initially acquired the commercial rights to biosimilar Adalimumab in 2022 through its acquisition of Viatris’ global biosimilars business. Viatris had previously in-licensed the product from FKB. Under the earlier arrangement, FKB manufactures and supplies the product to Biocon Biologics, which holds global commercial rights for HULIO.
Adalimumab is one of the three immunology biosimilars in Biocon Biologics’ overall portfolio, which underscores the Company’s strategic focus on expanding access to biologics for immune-mediated diseases worldwide.
About Biocon Biologics Limited
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its ‘lab to market’ capabilities to serve over 6.3 million patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. Biocon Biologics has commercialized 10 biosimilars from its portfolio which are addressing the patients’ needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of
1
==> picture [80 x 30] intentionally omitted <==
==> picture [132 x 30] intentionally omitted <==
20+ biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other noncommunicable diseases. The Company has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com; Follow us on X (formerly Twitter) : @BioconBiologics and LinkedIn : Biocon Biologics for company updates.
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceutical company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the U.S., Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com Follow-us on X ( formerly Twitter ) @bioconlimited and LinkedIn : @BioconLimited for company updates. For FY25 Integrated Annual Report of Biocon click here
| FOR MORE INFORMATION | |
|---|---|
| For Media | For Investors |
| Rumman Ahmed | Prashant Nair |
| Senior Director, Biocon Biologics | Head – Investor Relations, Biocon Biologics |
| +91 98451 04173 | +91 98200 95476 |
| [email protected] | [email protected] |
| Lance Longwell | |
| Public Relations Lead – Advanced Markets, | |
| Biocon Biologics | |
| +1 857 270 4391 | |
| [email protected] |
Forward-Looking Statements: Biocon
This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.
2